Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Apollo Hospitals Saves 41 Yr Old Farmer Who Waited 91 Days for a Heart Transplant with Mitral Chip Implant

Apollo Hospitals, Asia’s foremost and most trusted healthcare group, today announced a successful MitraClip implant on a 41-year-old male farmer who had waited for over three months in different hospitals for a heart transplant. The patient was back on his feet within a few days after the procedure, and might not even need a heart transplant.

Ms. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Group said, “As one of the few hospitals in India accredited to perform the MitraClip procedure, being able to save the life of a patient waiting for a heart transplant gives us the ability to offer hope to many others. Research has shown that using MitraClip as a bridge to heart transplantation is safe and may lead to functional improvements that permit patients to be removed from the transplant list. We are proud to have demonstrated this at Apollo Hospitals through the case of a 41-year-old male patient who was waiting for a heart transplant for over three months. The success of this case has renewed our commitment to taking this cutting edge and revolutionary medical innovation to the people who need it the most.”

Dr. Sai Satish, Senior Interventional Cardiologist, Apollo Hospitals said, “The MitraClip is a globally accepted procedure for patients with heart failure. For three years now we have been performing this procedure on patients and we have seen incredible results in the quality of life they are able to return to. Our experience in this domain has enabled us to achieve many milestones including back-to-back MitraClip implants in four very sick patients in just one day. Today, we are at pole position; 70% of all MitraClips in India to date have been performed at Apollo Hospitals and we are only looking at bigger milestones in the journey ahead.”

India’s first two scientific papers on MitraClip have both been published from Apollo Hopsitals. Dr. Sai Satish is involved in the authorship of the APAC guidelines for MitraClip implants. Asia’s first MitraClip training programme that included theory and four cases over two days was conducted at Apollo Hospitals, cementing its position as a Centre of Excellence in Interventional Cardiology.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy